ClinicalTrials.gg
CompletedNCT07279766DAN-COVIDUpdated Oct 6, 2026

Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19

A Phase 4 interventional study of mRNA-1273 (Moderna COVID-19 vaccine) in COVID-19, sponsored by Tor Biering-Sørensen. Completed at 2 sites in Denmark. Open to participants aged 50 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Tor Biering-Sørensen · Phase 4, Interventional, and Treatment

How we know

Updated Oct 6, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
41,060
Allocation
Randomized
Ages
50 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.

Enrollment
Largest of 36
41,060 · median 499
Started
2025
with 1 other
Phase 4
7 of 36
2 open now
Registered
35th of 36
by date

Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one has the largest enrollment, is one of 2 that started in 2025, is one of 7 in phase 4, and was the 35th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About 2019-nCoV Vaccine mRNA-1273

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 50 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, or all of them as a file.
02

Study summary

The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection. Participants will be randomized 1:1 to either COVID-19 vaccine or no COVID-19 vaccine.

Read the detailed description

The study is a pragmatic, registry-based, open-label, individually randomized trial. The Danish nationwide administrative health registries will be used for data collection including baseline information, follow-up data, and safety monitoring. The study aims to randomize a total of 285,000 participants. Participants will be individually randomized 1:1 to receive either a COVID-19 vaccine or no COVID-19 vaccine. The study is designed to assess the vaccine effectiveness of the COVID-19 vaccine vs. no COVID-19 vaccine on the risk of medically attended COVID-19 infection.

03

Conditions studied

  • COVID-19

Keywords

  • COVID-19
  • Vaccination
  • Pragmatic
  • Registry
  • Respiratory tract disease
  • Respiratory
  • Cardiovascular
04

Who can participate

Ages eligible
50 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50-64 years
  • form has been signed and dated

Exclusion criteria

Exclusion Criteria:

  • Medical conditions that increase the risk of severe COVID-19, which will be assessed through self-reporting. These medical conditions include:

    1. Asthma
    2. Cancer (excluding non-melanoma skin cancer)
    3. Cardiomyopathies
    4. Cerebrovascular disease
    5. Chronic kidney disease
    6. Chronic lung disease
    7. Cystic Fibrosis
    8. Dementia
    9. Diabetes
    10. Down syndrome
    11. Heart failure
    12. therapy
    13. Ischemic heart disease
    14. Liver disease
    15. Neurological/neuromuscular disease
    16. Psychiatric disease (psychotic, schizophrenic, schizotypal, depressive, and bipolar (affective) disorders).
    17. Severe obesity ( >35 kg/m2)
    18. Severe substance abuse
    19. Short bowel syndrome
    20. Solid organ transplant or hematological transplant
  • Apart from these, there are no specific exclusion criteria for this study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41,060 participants (actual)

Study arms

  • Experimental
    mRNA-1273 (Spikevax)

    COVID-19 vaccine single injection at day 0

    Biological: mRNA-1273 (Moderna COVID-19 vaccine)

  • No intervention
    No COVID-19 vaccine (control)

    Control arm, no COVID-19 vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Medically attended COVID-19

    Defined as a positive PCR test for SARS-CoV-2 or hospitalization for COVID-19-related respiratory tract disease

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

Secondary outcomes

  1. COVID-19-related hospitalization

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  2. COVID-19-related respiratory tract disease hospitalization

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  3. COVID-19-related cardio-respiratory disease hospitalization

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  4. All-cause respiratory tract disease hospitalization

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  5. All-cause cardio-respiratory hospitalization

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  6. All-cause lower respiratory tract disease hospitalization

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  7. All-cause hospitalization

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  8. COVID-19 death

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  9. All-cause death

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

Other outcomes

  1. COVID-19-related hospitalization (alternate definition)

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  2. Laboratory-confirmed COVID-19

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  3. Total length of hospital stays due to COVID-19-related respiratory tract disease

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  4. Composite of hospitalization for COVID-19 or pneumonia (ICD-10 codes only)

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  5. Hospitalization for any cardiovascular disease

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  6. Hospitalization due to any infectious disease

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  7. Hospitalization requiring mechanical ventilation

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  8. In-hospital mortality

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  9. Cardio-respiratory mortality

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  10. Respiratory mortality

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  11. Cardiovascular mortality

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  12. Intensive care unit admission

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  13. Laboratory-confirmed COVID-19 hospitalization

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

  14. Any hospital contact associated with laboratory-confirmed COVID-19

    Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

07

Study locations

2 sites
  • Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte
    Hellerup, 2900, Denmark
  • Danske Lægers Vaccinations Service
    Søborg, 2860, Denmark
08

References and documents

Individual participant data

Plan to share: Yes — In this trial, baseline and endpoint data will be collected from Danish administrative health registries, which are subject to Danish legislation and can only be made available to a third party under certain conditions. Please contact the sponsor-investigator in case of any inquiries.

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Aug 2026, 8 months.

Of 145 non-industry phase 4 interventional studies under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 8 months is below that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 4 and three quarters within 18.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2025
First posted
Dec 12, 2025
StartActual
Dec 11, 2025
Primary completionActual
Aug 26, 2026
CompletionActual
Sep 5, 2026was Aug 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 6, 2026
Study completion
Aug 2026→Sep 5, 2026 (actual)
Oct 6, 2026
Enrollment
285000 (estimated)→41060 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Active, not recruiting→Completed
    Study completion Aug 2026→Sep 5, 2026 (now actual)
    Enrollment 285000 (estimated)→41060 (actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07279766
Lead sponsor
Tor Biering-Sørensen
Collaborators
ModernaTX, Inc.
Responsible party
Tor Biering-Sørensen (Professor, MD, MSc, MPH, PhD, Herlev and Gentofte Hospital) — Sponsor-investigator
First posted
Dec 12, 2025
Start date
Dec 11, 2025
Primary completion
Aug 26, 2026
Completion
Sep 5, 2026
Last update
Oct 6, 2026

Study contacts

Tor Biering-Sørensen, MD, MSc, MPH, PhD
study chair · Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 2019-nCoV Vaccine mRNA-1273

Start the discussion